Medicare AdvantageMay 22, 2025
New specialty pharmacy medical step therapy requirements
Starting July 1, 2025, the following Part B medications from the current Clinical Criteria Guidelines will be included in our medical step therapy precertification review process.
Step therapy will apply to members upon precertification initiation in addition to the current medical necessity review.
Step therapy will not apply to members actively receiving the medications listed below.
Clinical Criteria Guidelines are publicly available at https://provider.bluemedadv.com. Visit the Clinical Criteria page to search for specific criteria.
Clinical UM Guidelines | Status | Drug(s) |
CC-0072 | Preferred | Pavblu (aflibercept-ayyh) |
CC-0072 | Non-preferred | Ahzantive (aflibercept-mrbb) |
CC-0072 | Non-preferred | Enzeevu (aflibercept-abzv) |
CC-0072 | Non-preferred | Opuviz (afibercept-yszy) |
CC-0072 | Non-preferred | Yesafili (aflibercept-jbvf) |
Blue Medicare Advantage is the trade name of Group Retiree Health Solutions, Inc., an independent licensee of the Blue Cross Blue Shield Association.
PAIBC-CR-081300-25-CPN81191
To view this article online:
Or scan this QR code with your phone